SCHEMBL3528218

SCHEMBL3528218

COc1ccc(CN2CCCCCC=CCCC(C(=O)O)NC(=O)C3CC(O[Si](C)(C)C(C)(C)C)C[N+]3C2=O)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP1 P03956 2/20 0.34
▸ MMP13 P45452 1/20 0.34
▸ KCNH2 Q12809 1/20 0.32
▸ MCHR1 Q99705 1/20 0.32
▸ HRH3 Q9Y5N1 1/20 0.31
▸ MMP3 P08254 1/20 0.31
▸ MMP9 P14780 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ THRB P10828 1/20 0.31
▸ ALOX15 P16050 1/20 0.31
▸ GRM2 Q14416 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ CYP2D6 P10635 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ OPRM1 P35372 2/20 0.30
▸ OPRL1 P41146 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL996970 0.92 MCHR1 (0.33) MMP1MMP13KCNH2MCHR1HRH3
SCHEMBL995145 0.85 MMP1 (0.34) MMP1MMP13HRH3MMP3MMP9
SCHEMBL996316 0.84 — —
SCHEMBL3308959 0.81 KCNH2 (0.36) KCNH2MCHR1MEN1KMT2A
SCHEMBL3309953 0.80 CTSB (0.33) MMP1MMP13KCNH2MCHR1MEN1
SCHEMBL3526341 0.78 ALDH1A1 (0.34) MMP1MMP13KCNH2MCHR1HRH3
SCHEMBL3552292 0.76 FAAH (0.31) —
SCHEMBL994826 0.74 ALDH1A1 (0.35) MMP1KCNH2MMP9KDM4EALOX15
SCHEMBL3811327 0.74 GAA (0.33) GAA
SCHEMBL2839916 0.72 ALDH1A1 (0.33) KCNH2MCHR1KDM4EALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666834-B2 Macrocyclic inhibitors of hepatitis C virus TIBOTEC PHARMACEUTICALS LTD. (IE) 2010-02-23 — — US disclosed
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus JANSSEN SCIENCES IRELAND UC (IE) 2009-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus HCCS, CBR1, CYP2B6 MMP1 3760/4885MMP13 3916/4885KCNH2 2258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback